Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Javrishvili Eye Microsu… | Healthcare Services | 24.3% | 85th pct | 312 |
| Medi | Healthcare Services | 23.6% | 82nd pct | 312 |
| I. Zhordanias Sakhelobi… | Healthcare Services | 21.7% | 79th pct | 312 |
| Hera 2011 | Healthcare Services | 11.8% | 57th pct | 312 |
| Sachkhere District Hosp… | Healthcare Services | -14.9% | 11th pct | 312 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Medi | Sachkhere District Hosp… | Hera 2011 | Javrishvili Eye Microsu… | I. Zhordanias Sakhelobi… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 82.6% | 8.7% | 88.4% | 53.6% | 35.6% |
| EBITDA Margin | 23.6% | -14.9% | 11.8% | 24.3% | 21.7% |
| EBITDAR | 3,200 | -1,964 | 1,601 | 3,032 | 1,935 |
| EBITDAR Margin | 23.6% | -14.9% | 12.8% | 24.3% | 21.7% |
| EBIT Margin | 23.6% | -45.2% | 8.5% | 11.2% | 19.2% |
| Net Profit Margin | 29.1% | -41.8% | 7.2% | 6.3% | 20.2% |
| Operating Expense % of Sales | 59.1% | 26.5% | 76.6% | 29.4% | 13.9% |
| Returns | |||||
| Return on Assets (ROA) | 25.0% | -23.5% | 9.3% | 4.2% | 29.7% |
| Return on Equity (ROE) | 25.4% | -31.3% | 10.1% | 6.4% | 39.4% |
| ROIC [EBIT / Invested Capital] | |||||
| 21.7% |
| -32.3% |
| 12.8% |
| 7.9% |
| 47.3% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 3.7% | 0.7% | 31.2% | 0.0% |
| Debt-to-Equity | 0.00x | 0.05x | 0.01x | 0.48x | 0.00x |
| Debt-to-EBITDA | 0.00x | N/A | 0.04x | 1.94x | 0.00x |
| Equity-to-Assets | 98.4% | 75.2% | 91.7% | 65.5% | 75.4% |
| Net Debt | -805 | 837 | -656 | 5,263 | -946 |
| Cash & Equivalents | 805 | 40 | 721 | 626 | 946 |
| Total Debt | N/A | 877 | 65 | 5,890 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 47.28x | 0.71x | 2.95x | 7.11x | 2.42x |
| Quick Ratio | 44.50x | 0.28x | 2.95x | 5.97x | 2.07x |
| Cash Ratio | 3.12x | 0.01x | 0.89x | 0.99x | 0.63x |
| Total Current Assets | 12,189 | 3,793 | 2,390 | 4,494 | 3,603 |
| Total Current Liabilities | 258 | 5,352 | 812 | 632 | 1,491 |
| Inventory | 718 | 2,309 | N/A | 721 | 517 |
| Trade Receivables | 145 | 1,444 | 1,471 | 2,778 | 2,140 |
| Trade Payables | 199 | 4,203 | 89 | 522 | 1,491 |
| Net Working Capital | 11,931 | -1,560 | 1,579 | 3,862 | 2,112 |
| Net Working Capital % of Revenue | 87.9% | -11.8% | 12.6% | 30.9% | 23.6% |
| Trade Working Capital | 663 | -450 | 1,382 | 2,977 | 1,166 |
| Trade Working Capital % of Revenue | 4.9% | -3.4% | 11.1% | 23.8% | 13.1% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 3.29x | 5.20x | N/A | 8.03x | 11.13x |
| Days Inventory Outstanding (DIO) | 110.9 | 70.2 | N/A | 45.4 | 32.8 |
| Receivables Turnover | 93.88x | 9.12x | 8.50x | 4.49x | 4.17x |
| Days Sales Outstanding (DSO) | 3.9 | 40.0 | 43.0 | 81.2 | 87.4 |
| Payables Turnover | 11.84x | 2.86x | 16.28x | 11.09x | 3.86x |
| Days Payable Outstanding (DPO) | 30.8 | 127.7 | 22.4 | 32.9 | 94.6 |
| Cash Conversion Cycle | 84.0 days | -17.5 days | 20.5 days | 93.7 days | 25.6 days |
| Asset Turnover | 0.86x | 0.56x | 1.28x | 0.66x | 1.47x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 4,477 | 3,803 | N/A | 2,007 | 2,462 |
| Free Cash Flow (OCF − Capex proxy) | 608 | 171 | N/A | -579 | 690 |
| Cash Conversion (OCF / EBITDA) | 139.9% | N/A | N/A | 66.2% | 127.2% |
| Dividends Declared | 1,089 | 0 | N/A | 326 | 635 |
| Dividend Payout Ratio | 27.6% | N/A | N/A | 41.5% | 35.3% |